Large‐for‐gestational age · preventing gestational diabetes
Probiotics showed no clear difference in large‐for‐gestational age compared with placebo (moderate certainty).
1 finding from 1 review
Perinatal mortality · preventing gestational diabetes
Probiotics showed no clear difference in perinatal mortality (stillbirth and neonatal mortality) compared with placebo (low certainty).
1 finding from 1 review
Proportion of responders (at least 50% seizure frequency reduction in PGTCS) · people with juvenile myoclonic epilepsy
It is very uncertain whether topiramate changes proportion of responders (at least 50% seizure frequency reduction… compared with placebo (very low certainty).
1 finding from 1 review
Proportion of participants who experienced at least one AE and individual AEs · people with juvenile myoclonic epilepsy
1 finding from 1 review
Seizure freedom · people with juvenile myoclonic epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment withdrawal · people with epilepsy
1 finding from 1 review
Seizure freedom · people with epilepsy
1 finding from 1 review
All adverse effects · people with epilepsy
1 finding from 1 review
Proportion with complete resolution of a target tophus · participants with tophi in gout
Pegloticase every two weeks (biweekly) probably leads to higher proportion with complete resolution of tophi compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Serum urate normalisation ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Function ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events · participants with tophi in gout
Monthly pegloticase probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Total adverse events · participants with tophi in gout
Monthly pegloticase showed no clear difference in total adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Proportion with complete resolution of a target tophus · participants with tophi in gout
Lesinurad 200 mg plus allopurinol showed no clear difference in proportion with complete resolution of a target tophus compared with placebo plus allopurinol (moderate certainty).
1 finding from 1 review
Proportion with complete resolution of a target tophus · participants with tophi in gout
Lesinurad 400 mg plus allopurinol showed no clear difference in proportion with complete resolution of a target tophus compared with placebo plus allopurinol (moderate certainty).
1 finding from 1 review
Joint pain reduction ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Quality of life ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Serum urate normalisation ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Function ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review